BPC-157 searches from women skew toward two very specific angles: endometriosis and general "for women" framing that most existing content doesn't address directly. This guide covers both — along with a regulatory update that's more current than almost anything else published on this topic.
What BPC-157 Is
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protective protein sequence found in human gastric juice. It's one of the most extensively studied peptides in preclinical (animal) research for gut lining protection, tendon and muscle repair, and modulation of the brain-gut axis. Researcher Predrag Sikiric's group, based in Croatia, has published the majority of the foundational mechanistic work over the past two decades, documenting effects across muscle healing, gut protection, and even behavioral and mood-related pathways connected to the gut-brain axis.
The Regulatory Status — Current as of July 2026
BPC-157's compounding status has moved twice this year. In 2023, the FDA placed it on the Category 2 bulk substances list under Section 503A, citing safety concerns and effectively blocking compounding pharmacies from preparing it. On April 15, 2026, the FDA removed BPC-157 from Category 2, opening the door to a formal Pharmacy Compounding Advisory Committee (PCAC) review. That review is scheduled for July 23–24, 2026. Published briefing documents ahead of the meeting indicate FDA staff are proposing BPC-157 not be added to the 503A positive bulks list — though this is a staff proposal for the advisory committee to consider, not a final agency determination, and the PCAC's eventual recommendation is itself advisory rather than binding on the FDA.
In plain terms: BPC-157 is not FDA-approved for any human use, has never completed that process, and its compounding-pharmacy pathway is actively unsettled pending a review happening this month. Anyone telling you its legal status is simple right now is oversimplifying a genuinely moving situation. We'll update this page after the July meeting.
The Gut-Healing Research
The strongest and most consistent BPC-157 data is preclinical: rodent studies showing accelerated healing of gut lining damage, protective effects against NSAID-induced ulceration, and modulation of inflammatory pathways along the gut-brain axis. This body of animal research is genuinely large and consistent, which is part of why interest in human application has grown despite the absence of large human trials.
On the human side, evidence is much thinner. A notable exception is a small pilot study — not a large randomized trial — in which 12 women with severe interstitial cystitis (a chronic bladder pain condition) received localized BPC-157 injections, with the majority reporting meaningful symptom improvement. That's a real, published data point, but it's a single pilot study in a specific condition, not a broad human efficacy trial, and it should be weighted accordingly.
The Endometriosis Connection: What's Actually Established
Here's where accuracy matters most. There is no published human trial of BPC-157 specifically for endometriosis. What does exist is a growing body of research on the gut-immune connection within endometriosis itself: a 2026 case-control study found women with endometriosis-related infertility show a distinct gut microbiome signature, with specific bacterial shifts correlating with inflammatory markers like IL-6. Endometriosis is increasingly understood as a condition with a meaningful gut-immune axis component, not solely a localized reproductive-tissue disease.
That's the mechanistic bridge worth understanding: BPC-157's best-documented effects are exactly in that gut-lining-protection, inflammation-modulation space. It is reasonable research interest — not an established treatment — to ask whether a compound with strong gut-protective preclinical data might be relevant to a condition now understood to have a real gut-immune inflammatory component. That is different from claiming BPC-157 treats endometriosis, which the current evidence does not support.
Where to Source It
What We Don't Know
- No completed randomized controlled trial has tested BPC-157 in women with endometriosis specifically.
- Optimal dosing, frequency, and duration are not established from human data — most protocols circulating online derive from animal-study dosing scaled by body weight, not from human pharmacokinetic trials.
- Long-term safety, including any interaction with reproductive hormones or hormone-sensitive conditions, has not been studied in humans.
- Purity and sourcing consistency vary significantly across suppliers, which is a separate risk from the compound's biological effects.
How This Fits With Other Approaches
Women researching BPC-157 for gut-related symptoms alongside broader hormonal or inflammatory concerns often look at it alongside KPV (a smaller anti-inflammatory peptide fragment with gut-specific research) or alongside a broader hormonal-support approach if perimenopause or PCOS-related inflammation is also a factor.
Not sure where to start?
Answer 5 quick questions about your life stage and goals — our quiz matches you to 1–3 peptides ranked by evidence strength.
Take the 2-Minute Quiz →